Investors

September 16, 2026

Gossamer Bio Appoints Greg Ciongoli to Board of Directors

September 11, 2026

Gossamer Bio Announces Effectiveness of 1-for-80 Reverse Stock Split

September 9, 2026

Gossamer Bio Announces 1-for-80 Reverse Stock Split

September 4, 2026

Gossamer Bio to Present at Cantor Global Healthcare Conference

August 21, 2026

Gossamer Bio Announces Up to $250 Million Structured Private Placement, Including $150 Million of Committed Capital, to Fund Seralutinib Through Potential FDA Approval

August 13, 2026

Gossamer Bio Announces Second Quarter 2026 Financial Results and Provides Business Update

July 27, 2026

Gossamer Bio Announces FDA Regulatory Update and Reacquisition of Worldwide Rights Related to Seralutinib and Provides a Business Update

July 1, 2026

Gossamer Bio, Inc. Announces Determination of Conversion Rate for 7.50% Convertible Senior Secured First Lien Notes due 2030 and Exercise Price for Purchase Warrants

June 17, 2026

Gossamer Bio, Inc. Announces Final Tender Results for Exchange Offer and Consent Solicitation with Respect to Existing Convertible Notes

June 3, 2026

Gossamer Bio, Inc. Announces Early Tender Results and Early Settlement for Exchange Offer and Consent Solicitation with Respect to Existing Convertible Notes